Altered states: Selectively drugging the Hsp90 cancer chaperone

Trends in Molecular Medicine

Volumn 10, Issue 2, 2004, Pages 47-51

  Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHAPERONE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; ONCOPROTEIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER INHIBITION; CANCER RESEARCH; CLINICAL TRIAL; DRUG TARGETING; HUMAN; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 1142273472     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2003.12.005     Document Type: Short Survey

References (29)

1. Workman P. The opportunities and challenges of personalised genome-based molecular therapies for cancer: targets, technologies and molecular chaperones. Cancer Chemother. Pharmacol. 52:(Suppl. 1):2003;S45-S46.
2. Workman, P. and Kaye, S.B., eds (2001) A Trends Guide to Cancer Therapeutics: A Supplement to Trends in Molecular Medicine (Vol. 8, No. 4), Elsevier Science.
3. Weinstein I.B. Addiction to oncogenes - the Achilles heal of cancer. Science. 297:2002;63-64.
4. Workman P. Cancer genome targets: RAF-ing up tumour cells to overcome oncogene addiction. Expert Rev. Anticancer Ther. 2:2002;611-614.
5. Workman, P., ed. (2003) Hsp90 molecular chaperone inhibitors: opportunities and challenges. Curr. Cancer Drug Targets 3 (5).
6. Isaacs J.S., et al. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 3:2003;213-217.
7. Maloney A., Workman P. Hsp90 as a new therapeutic target for cancer therapy. Expert Opin. Biol. Ther. 2:2002;3-24.
8. Kamal A., et al. A high affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 425:2003;407-410.
9. Kelland L.R., et al. DT-diaphorase expression and tumour cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. 91:1999;1940-1949.
10. Solit D.B., et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER2/Neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 8:2002;986-993.
11. Banerji U., et al. Preclinical and clinical activity of the molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in malignant melanoma. Proc. Am. Assoc. Cancer Res. 44:2003;677.
12. Sausville E.A., et al. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr. Cancer Drug Targets. 3:2003;377-383.
13. Whitesell L., et al. The stress response: implications for the clinical development of Hsp90 inhibitors. Curr. Cancer Drug Targets. 3:2003;349-358.
14. Hanahan G., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
15. Rutherford S.L., Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature. 396:1998;336-342.
16. Quietsch C., et al. Hsp90 as a capacitor or phenotypic variation. Nature. 417:2002;618-624.
17. Lindquist S.L., Henikoff S. Self-perpetuating states in biology, disease and genetics. Proc. Natl. Acad. Sci. U. S. A. 99:(Suppl. 4):2002;16377-16380.
18. Chiosis G., et al. 17AAG: low target binding affinity and potent cell activity - finding an explanation. Mol. Cancer Ther. 2:2003;123-129.
19. Egorin M.J., et al. PC3 human prostate xenograft retention of, and oncoprotein modulation by, 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in vivo. Proc. Am. Assoc. Cancer Res. 40:1999;3409.
20. Workman P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol. Cancer Ther. 2:2003;131-138.
21. Prodromou C., Pearl L.H. Structure and functional relationships of Hsp90. Curr. Cancer Drug Targets. 3:2003;301-323.
22. Panaretou B., et al. Activation of the ATPase activity of Hsp90 by the stress-regulated co-chaperone Aha1. Mol. Cell. 10:2002;1307-1318.
23. McLaughlin S.H., et al. Stimulation of the weak ATPase activity of human Hsp90 by a client protein. J. Mol. Biol. 315:2002;787-798.
24. Schulte T., Neckers L.M. The benzoquinone ansamycin 17-allylamino-17- demethoxygeldanamycin binds to Hsp90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 42:1998;273-279.
25. Roe S.M., et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumour antibiotics radicicol and geldanamycin. J. Med. Chem. 42:1999;260-266.
26. Chiosis G., et al. Development of purine-scaffold small molecule inhibitors of Hsp90. Curr. Cancer Drug Targets. 3:2003;371-376.
27. Schnur R.C., Corman M.L. Tandem [3,3]-sigmatropic rearrangements in an ansamycin - stereospecific conversion of an (S)-allylic alcohol to an (S)-allylic amine derivative. J. Org. Chem. 59:1994;2581-2584.
28. Neckers L., Lee Y.L. The rules of attraction. Nature. 425:2003;357-358.
29. Jez J.M., et al. Crystal structure and molecular modelling of 17-DMAG in complex with human Hsp90. Chem. Biol. 10:2003;361-368.